Table 3.
Characteristics of patients who experienced severe immune-related adverse events (irAEs).
| Category | Age/Sex | Histology | Immune-related adverse events | Th17/Th1pre | eTregpost/pre | Ki-67pre | CD8TNFpost | CD4TNFpost | Preexisting autoimmune syndrome | Anti-PD-1 agent | Time to irAEs (wks) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Th17-related | 60/F | Thymoma (B3) | G4 Glomerulonephritis | 2.0 | 1.7 | 18.0 | 0.2 | 7.4 | - | Pembrolizumab | 13 |
| 64/F | Thymoma (B2) | G4 Myocarditis, G3 hypothyroidism, G3 hepatitis | 1.0 | 1.2 | 8.7 | 6.9 | 6.5 | - | Pembrolizumab | 4 | |
| 51/F | Thymoma (B2) | G4 Myocarditis | 1.4 | 1.1 | 14.4 | 3.0 | 3.7 | - | Pembrolizumab | 4 | |
| TNF-related | 65/M | Squamous cell ca. | G3 Pneumonitis | 0.04 | 1.1 | 11.3 | 27.1 | 7.8 | - | Pembrolizumab | 4 |
| 72/M | Squamous cell ca. | G3 Hypothyroidism | 0.08 | 1.2 | 23.3 | 22.3 | 18.4 | - | Nivolumab | 25 | |
| 57/M | Squamous cell ca. | G5 Pneumonitis | 0.05 | 1.0 | 20.7 | 13.8 | 11.2 | - | Pembrolizumab | 4 | |
| 43/M | Thymic carcinoma | G3 Hepatitis | 0.2 | 0.7 | 10.3 | 22.5 | 21.0 | - | Pembrolizumab | 4 | |
| 88/M | Squamous cell ca. | G3 Hypothyroidism | 0.003 | 1.2 | 13.1 | 18.6 | 28.4 | - | Nivolumab | 5 | |
| Treg-related | 26/M | Thymic carcinoma | G4 Myasthenia gravis | 0.5 | 0.4 | 22.6 | 2.2 | 8.2 | - | Pembrolizumab | 4 |
| (or CD8-related Treg-uncompensated) | 66/F | Thymoma (B2) | G4 Hepatitis, G3 colitis | 0.003 | 0.7 | 24.6 | 0.2 | 7.4 | Myasthenia gravis |
Pembrolizumab | 1 |
| CD8-related | 52/M | Adenocarcinoma | G3 Pneumonitis | 0.3 | 0.9 | 38.9 | 3.5 | 8.6 | - | Pembrolizumab | 4 |
| (or CD8-related Treg-uncompensated) | 59/M | Thymic carcinoma | G3 Subacute myoclonus | 0.3 | 1.4 | 34.0 | 3.4 | 5.6 | - | Pembrolizumab | 28 |
| 66/M | Squamous cell ca. | G3 Hepatitis | 0.4 | 1.2 | 40.9 | 4.0 | 4.4 | - | Nivolumab | 1 |
Th17/Th1pre, ratio of Th17 and Th1 cells pre-treatment; eTregpost/pre, fold change of the frequency of eTreg cells posttreatment; Ki-67post, percentage of Ki-67+ cells among PD-1+CD8+ T cells posttreatment; CD8TNFpost, percentage of TNF-α+ cells among CD8+ T cells posttreatment; CD4TNFpost, percentage of TNF-α+ cells among CD4+ T cells posttreatment.